Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-12-19 4:15 pm Sale | 13G | Xilio Therapeutics Inc. XLO | GILEAD SCIENCES INC. GILD | 0 0.000% | -7,345,473 (Position Closed) | View |
| 2024-11-14 5:44 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | Bain Capital Life Sciences Fund II L.P. | 4,566,817 11.000% | 3,218,135 (+238.61%) | View |
| 2024-11-14 4:30 pm Sale | 13G | Xilio Therapeutics Inc. XLO | Atlas Venture Fund XI L.P. | 0 0.000% | -2,023,402 (Position Closed) | View |
| 2024-11-12 4:50 pm Unchanged | 13G | Xilio Therapeutics Inc. XLO | Rock Springs Capital Management LP | 3,003,259 6.830% | 0 (Unchanged) | View |
| 2024-11-12 10:40 am Sale | 13G | Xilio Therapeutics Inc. XLO | FMR LLC | 1,395,853 3.175% | -511,818 (-26.83%) | View |
| 2024-09-27 9:36 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | GKCC LLC | 7,000,000 15.900% | 7,000,000 (New Position) | View |
| 2024-07-31 07:46 am Unchanged | 13G | Xilio Therapeutics Inc. XLO | TAKEDA PHARMACEUTICAL CO LTD TAK | 1,475,121 4.000% | 0 (Unchanged) | View |
| 2024-04-05 4:31 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | GILEAD SCIENCES INC. GILD | 7,345,473 19.900% | 7,345,473 (New Position) | View |
| 2024-04-05 2:51 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | Rock Springs Capital Management LP | 3,003,259 8.710% | 1,562,500 (+108.45%) | View |
| 2024-02-14 2:12 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | Rock Springs Capital Management LP | 1,440,759 5.230% | 1,440,759 (New Position) | View |
| 2024-02-06 4:04 pm Sale | 13G | Xilio Therapeutics Inc. XLO | Octagon Capital Advisors LP | 0 0.000% | -1,785,000 (Position Closed) | View |
| 2024-02-05 4:01 pm Sale | 13G | Xilio Therapeutics Inc. XLO | Octagon Capital Advisors LP | 1,785,000 6.480% | -640,000 (-26.39%) | View |
| 2023-04-10 4:57 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | MRL Ventures Fund LLC | 1,483,414 5.400% | 1,483,414 (New Position) | View |
| 2023-02-09 08:14 am Sale | 13G | Xilio Therapeutics Inc. XLO | FMR LLC | 1,907,671 6.944% | -662,599 (-25.78%) | View |
| 2023-01-25 4:01 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | Octagon Capital Advisors LP | 2,425,000 8.830% | 2,425,000 (New Position) | View |
| 2022-12-29 5:24 pm Sale | 13G | Xilio Therapeutics Inc. XLO | Flynn James E | 0 0.000% | -2,154,061 (Position Closed) | View |
| 2022-11-14 4:43 pm Sale | 13G | Xilio Therapeutics Inc. XLO | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -2,002,217 (Position Closed) | View |
| 2022-02-14 4:11 pm Purchase | 13G | Xilio Therapeutics Inc. XLO | RA CAPITAL MANAGEMENT L.P. | 2,002,217 7.300% | 469,450 (+30.63%) | View |
| 2022-02-14 06:42 am Unchanged | 13G | Xilio Therapeutics Inc. XLO | Bain Capital Life Sciences Fund II L.P. | 1,348,682 4.900% | 0 (Unchanged) | View |
| 2022-02-11 4:14 pm Sale | 13G | Xilio Therapeutics Inc. XLO | Flynn James E | 2,154,061 7.840% | -133,883 (-5.85%) | View |